292 related articles for article (PubMed ID: 14595649)
1. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.
McGeer PL; Schwab C; Parent A; Doudet D
Ann Neurol; 2003 Nov; 54(5):599-604. PubMed ID: 14595649
[TBL] [Abstract][Full Text] [Related]
2. Acute and chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administrations elicit similar microglial activation in the substantia nigra of monkeys.
Vázquez-Claverie M; Garrido-Gil P; San Sebastián W; Izal-Azcárate A; Belzunegui S; Marcilla I; López B; Luquin MR
J Neuropathol Exp Neurol; 2009 Sep; 68(9):977-84. PubMed ID: 19680145
[TBL] [Abstract][Full Text] [Related]
3. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys.
Miklossy J; Doudet DD; Schwab C; Yu S; McGeer EG; McGeer PL
Exp Neurol; 2006 Feb; 197(2):275-83. PubMed ID: 16336966
[TBL] [Abstract][Full Text] [Related]
4. Glial reactions in Parkinson's disease.
McGeer PL; McGeer EG
Mov Disord; 2008 Mar; 23(4):474-83. PubMed ID: 18044695
[TBL] [Abstract][Full Text] [Related]
5. Long-lasting reactive changes observed in microglia in the striatal and substantia nigral of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Yasuda Y; Shinagawa R; Yamada M; Mori T; Tateishi N; Fujita S
Brain Res; 2007 Mar; 1138():196-202. PubMed ID: 17275793
[TBL] [Abstract][Full Text] [Related]
6. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure fails to produce delayed degeneration of substantia nigra neurons in monkeys.
Garrido-Gil P; Belzunegui S; San Sebastián W; Izal-Azcárate A; López B; Marcilla I; Luquin MR
J Neurosci Res; 2009 Feb; 87(2):586-97. PubMed ID: 18798285
[TBL] [Abstract][Full Text] [Related]
7. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
8. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure.
Barcia C; Sánchez Bahillo A; Fernández-Villalba E; Bautista V; Poza Y Poza M; Fernández-Barreiro A; Hirsch EC; Herrero MT
Glia; 2004 May; 46(4):402-9. PubMed ID: 15095370
[TBL] [Abstract][Full Text] [Related]
9. Inflammation in Parkinson's disease: causative or epiphenomenal?
Hald A; Van Beek J; Lotharius J
Subcell Biochem; 2007; 42():249-79. PubMed ID: 17612055
[TBL] [Abstract][Full Text] [Related]
10. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Sawada H; Hishida R; Hirata Y; Ono K; Suzuki H; Muramatsu S; Nakano I; Nagatsu T; Sawada M
J Neurosci Res; 2007 Jun; 85(8):1752-61. PubMed ID: 17469135
[TBL] [Abstract][Full Text] [Related]
11. Microglial response is poorly correlated with neurodegeneration following chronic, low-dose MPTP administration in monkeys.
Hurley SD; O'Banion MK; Song DD; Arana FS; Olschowka JA; Haber SN
Exp Neurol; 2003 Dec; 184(2):659-68. PubMed ID: 14769357
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease.
Watanabe Y; Himeda T; Araki T
Med Sci Monit; 2005 Jan; 11(1):RA17-23. PubMed ID: 15614202
[TBL] [Abstract][Full Text] [Related]
13. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease.
Zecca L; Wilms H; Geick S; Claasen JH; Brandenburg LO; Holzknecht C; Panizza ML; Zucca FA; Deuschl G; Sievers J; Lucius R
Acta Neuropathol; 2008 Jul; 116(1):47-55. PubMed ID: 18343932
[TBL] [Abstract][Full Text] [Related]
14. Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment.
Knyihár-Csillik E; Csillik B; Pákáski M; Krisztin-Péva B; Dobó E; Okuno E; Vécsei L
Neuroscience; 2004; 126(4):899-914. PubMed ID: 15207325
[TBL] [Abstract][Full Text] [Related]
15. Persistent phagocytic characteristics of microglia in the substantia nigra of long-term Parkinsonian macaques.
Barcia C; Ros CM; Ros-Bernal F; Gómez A; Annese V; Carrillo-de Sauvage MA; Yuste JE; Campuzano CM; de Pablos V; Fernández-Villalba E; Herrero MT
J Neuroimmunol; 2013 Aug; 261(1-2):60-6. PubMed ID: 23759319
[TBL] [Abstract][Full Text] [Related]
16. Neurotoxicity of MPTP to migrating neuroblasts: studies in acute and subacute mouse models of Parkinson's disease.
He XJ; Yamauchi H; Uetsuka K; Nakayama H
Neurotoxicology; 2008 May; 29(3):413-20. PubMed ID: 18387672
[TBL] [Abstract][Full Text] [Related]
17. Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits.
Beach TG; Sue LI; Walker DG; Lue LF; Connor DJ; Caviness JN; Sabbagh MN; Adler CH
Acta Neuropathol; 2007 Oct; 114(4):419-24. PubMed ID: 17639428
[TBL] [Abstract][Full Text] [Related]
18. Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine)-induced apoptosis in nigral neurons of mice.
Aoki E; Yano R; Yokoyama H; Kato H; Araki T
Exp Mol Pathol; 2009 Feb; 86(1):57-64. PubMed ID: 19027004
[TBL] [Abstract][Full Text] [Related]
19. Ghrelin antagonizes MPTP-induced neurotoxicity to the dopaminergic neurons in mouse substantia nigra.
Jiang H; Li LJ; Wang J; Xie JX
Exp Neurol; 2008 Aug; 212(2):532-7. PubMed ID: 18577498
[TBL] [Abstract][Full Text] [Related]
20. Sparing of orexin-A and orexin-B neurons in the hypothalamus and of orexin fibers in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated macaques.
Bensaid M; Tandé D; Fabre V; Michel PP; Hirsch EC; François C
Eur J Neurosci; 2015 Jan; 41(1):129-36. PubMed ID: 25328140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
